Presentation is loading. Please wait.

Presentation is loading. Please wait.

Figure MRI brain comparison prior and after treatment and brain biopsy findings MRI brain comparison prior and after treatment and brain biopsy findings.

Published by范 廖 Modified over 5 years ago

Similar presentations

Presentation on theme: "Figure MRI brain comparison prior and after treatment and brain biopsy findings MRI brain comparison prior and after treatment and brain biopsy findings."— Presentation transcript:

1 Figure MRI brain comparison prior and after treatment and brain biopsy findings
MRI brain comparison prior and after treatment and brain biopsy findings MRI brain T2 FLAIR before (A) and after (B) treatment with steroids. Biopsy: (C) H&E staining, the circle showing white matter gliosis. (D) H&E staining, the arrows showing scant perivascular mature lymphocytes. (E) GFAP immunostaining, the circles showing the reactive gliosis. (F) T cell marker CD3 (+) immunostaining, the arrows showing lymphocytes around the blood vessels. Daniel G. Di Luca et al. Neurology 2019;92:e2832-e2837 © 2019 American Academy of Neurology

Download ppt "Figure MRI brain comparison prior and after treatment and brain biopsy findings MRI brain comparison prior and after treatment and brain biopsy findings."

Similar presentations

Neurology Resident and Fellow Section

Neurology Resident and Fellow Section
Juxtavascular astrocytes are enriched in nuclear Aryl hydrocarbon receptor immunostaining at the stab wound injury site in WT mice Juxtavascular astrocytes.

Juxtavascular astrocytes are enriched in nuclear Aryl hydrocarbon receptor immunostaining at the stab wound injury site in WT mice Juxtavascular astrocytes.
Epilepsy, hippocampal sclerosis and amygdalar atrophy following H1N1-influenza- associated encephalopathy in an adult  Shirin Karimi, Taufik A. Valiante,

Epilepsy, hippocampal sclerosis and amygdalar atrophy following H1N1-influenza- associated encephalopathy in an adult  Shirin Karimi, Taufik A. Valiante,
Figure 2. A patient with multifocal nodular lesions diagnosed with CNS tuberculosis A patient with multifocal nodular lesions diagnosed with CNS tuberculosis.

Figure 2. A patient with multifocal nodular lesions diagnosed with CNS tuberculosis A patient with multifocal nodular lesions diagnosed with CNS tuberculosis.
Figure 4 Ex vivo synovial tissue culture viability

Figure 4 Ex vivo synovial tissue culture viability
Tumor cell agglutination and not solely cytokine release as mechanism of adverse reactions during anti-CD20 monoclonal antibody (IDEC-C2B8, rituximab)

Tumor cell agglutination and not solely cytokine release as mechanism of adverse reactions during anti-CD20 monoclonal antibody (IDEC-C2B8, rituximab)
Histopathologic features (all images at ×10 magnification).

Histopathologic features (all images at ×10 magnification).
Figure 2 Association of serum IgG reactivity with MRI measures of disease severity Association of serum IgG reactivity with MRI measures of disease severity.

Figure 2 Association of serum IgG reactivity with MRI measures of disease severity Association of serum IgG reactivity with MRI measures of disease severity.
Figure Vertebral artery angiogram and tissue pathology

Figure Vertebral artery angiogram and tissue pathology
Figure Neuroimaging and pathology

Figure Neuroimaging and pathology
Figure 3 Immunohistochemical analyses of positive and negative Epstein-Barr virus (EBV) control tissues using immunostaining Immunohistochemical analyses.

Figure 3 Immunohistochemical analyses of positive and negative Epstein-Barr virus (EBV) control tissues using immunostaining Immunohistochemical analyses.
Figure 1 Coronal MRI images showing the evolution of white matter abnormality and atrophy of patient 1 Coronal MRI images showing the evolution of white.

Figure 1 Coronal MRI images showing the evolution of white matter abnormality and atrophy of patient 1 Coronal MRI images showing the evolution of white.
Figure Brain MRI of the patient throughout the disease course(A) Brain MRI at the time of cerebral toxoplasmosis diagnosis (a) and after 1 month of toxoplasmosis.

Figure Brain MRI of the patient throughout the disease course(A) Brain MRI at the time of cerebral toxoplasmosis diagnosis (a) and after 1 month of toxoplasmosis.
Figure 1 Treg percentage and suppressive function increased during each round of Treg infusions Treg percentage and suppressive function increased during.

Figure 1 Treg percentage and suppressive function increased during each round of Treg infusions Treg percentage and suppressive function increased during.
Figure 5 Treatment with fingolimod raises the activation threshold of monocytes in MS Peripheral blood mononuclear cells from 8 healthy donors, 7 patients.

Figure 5 Treatment with fingolimod raises the activation threshold of monocytes in MS Peripheral blood mononuclear cells from 8 healthy donors, 7 patients.
Figure 2 Immunopathologic analysis of all 3 Rasmussen encephalitis cases Immunopathologic analysis of all 3 Rasmussen encephalitis cases (A) Perivascular.

Figure 2 Immunopathologic analysis of all 3 Rasmussen encephalitis cases Immunopathologic analysis of all 3 Rasmussen encephalitis cases (A) Perivascular.
Figure 1 Histopathologic features of a chronic active and a chronic plaque in the MS brain Histopathologic features of a chronic active and a chronic plaque.

Figure 1 Histopathologic features of a chronic active and a chronic plaque in the MS brain Histopathologic features of a chronic active and a chronic plaque.
Figure 1 Muscle biopsy images demonstrating a pauci-immune necrotizing autoimmune myopathy in illustrative cases 1 and 2 (A–D) Case 1 deltoid muscle. Muscle.

Figure 1 Muscle biopsy images demonstrating a pauci-immune necrotizing autoimmune myopathy in illustrative cases 1 and 2 (A–D) Case 1 deltoid muscle. Muscle.
Figure 1. Prebiopsy and postbiopsy MRI

Figure 1. Prebiopsy and postbiopsy MRI
Figure Brain MRI and biopsy specimens from the pontine lesion

Figure Brain MRI and biopsy specimens from the pontine lesion

Similar presentations

Ads by Google